Antioxidant activity of calycosin against α-synuclein amyloid fibrils-induced oxidative stress in neural-like cells as a model of preventive care studies in Parkinson's disease

Pan, Qichen; Ban, Yunchao; Khan, Suliman

doi:10.1016/j.ijbiomac.2021.03.186

Cited by 24 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although GSH is not the sole antioxidant involved in PD, it seems to relate with disease severity because GSH depletion starts before other PD symptoms, including diminished complex I activity in the mitochondria and the development of Lewy bodies [ 42 , 43 ]. Increasing GSH levels in the brain is a possible therapy for PD, and multiple experimental investigations have shown this strategy works [ 44 , 45 ]. We discovered that B. breve CCFM1067 intake enhances the antioxidant capacity of the central nervous system, which helped PD mice reduce superoxide toxicity and alleviate oxidative stress.…”

Section: Discussionmentioning

confidence: 99%

Neuroprotective Effects of Bifidobacterium breve CCFM1067 in MPTP-Induced Mouse Models of Parkinson’s Disease

Chu

et al. 2022

Nutrients

View full text Add to dashboard Cite

There is mounting evidence that the microbiota–gut–brain axis (MGBA) is critical in the pathogenesis and progression of Parkinson’s disease (PD), suggesting that probiotic therapy restoring gut microecology may slow down disease progression. In this study, we examined the disease-alleviating effects of Bifidobacterium breve CCFM1067, orally administered for 5 weeks in a PD mouse model. Our study shows that supplementation with the probiotic B. breve CCFM1067 protected dopaminergic neurons and suppressed glial cell hyperactivation and neuroinflammation in PD mice. In addition, the antioxidant capacity of the central nervous system was enhanced and oxidative stress was alleviated. Moreover, B. breve CCFM1067 protected the blood–brain and intestinal barriers from damage in the MPTP-induced mouse model. The results of fecal microbiota analysis showed that B. breve CCFM1067 intervention could act on the MPTP-induced microecological imbalance in the intestinal microbiota, suppressing the number of pathogenic bacteria (Escherichia-Shigella) while increasing the number of beneficial bacteria (Bifidobacterium and Akkermansia) in PD mice. In addition, the increase in short chain fatty acids (acetic and butyric acids) may explain the anti-inflammatory action of B. breve CCFM1067 in the gut or brain of the MPTP-induced PD mouse model. In conclusion, we demonstrated that the probiotic B. breve CCFM1067, which can prevent or treat PD by modulating the gut–brain axis, can be utilized as a possible new oral supplement for PD therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Neuroprotective Effects of Bifidobacterium breve CCFM1067 in MPTP-Induced Mouse Models of Parkinson’s Disease

Chu

et al. 2022

Nutrients

View full text Add to dashboard Cite

show abstract

“…The hydrophobic portions of the protein can be bonded by calycosin, limiting hydrophobichydrophobic interactions, protein aggregation, and neurotoxicity in PD. [109] Cheng et al illustrated that natural product curcumin (Cur) and ultrasmall nanoscale coordination polymers (NCPs) coordinated by ferric ions were used to create the curcuminbased NCP. Curcumin-based NCP provides effective PD therapy in a mouse PD model induced by MPTP by scavenging excessive radicals, prolonging blood circulation, enhancing BBB crossing, and reducing neuroinflammation.…”

Section: Antioxidant Therapymentioning

confidence: 99%

Parkinson's Disease: Current Status, Diagnosis, and Treatment Using Nanomedicines

Hasan

Roy

Chang

2023

Advanced Therapeutics

View full text Add to dashboard Cite

Parkinson's disease (PD) is a chronic, and highly neurodegenerative disorder with complex pathological processes. The features for neuropathological identification of PD include α‐synuclein (α‐syn) protein aggregates, oxidative stress, metal ion dyshomeostasis, neurotransmitter deficiencies, and mitochondrial dysfunction. Currently, no definite treatment paradigm can completely cure PD patients, which is increasing globally over the past few decades. The existence of the blood‐brain barrier (BBB) restricts the conventional treatment processes and makes the therapeutic delivery to the brain a bit more challenging. Therefore, developing new useful medicines for improving brain distribution is vital to overcome BBB and helping the early diagnosis and treatment of PD. In this review, the current limitations of conventional drugs are highlighted and the development of new medicines to overcome such limitations is covered. This work will provide insight into the direction for designing novel efficient nanomedicines for the early diagnosis and treatment of PD.

show abstract

“…Previous studies reported that calycosin (i.p. administration for 7 days at the doses of 15 or 30 mg/kg/day) mitigated MPTP-induced PD-like conditions in mice by inhibiting the activation of TLR-NF-κβ and MAPK signaling-mediated inflammatory responses [207], and through its antioxidant properties which limited α-synuclein-induced neurotoxicity [208]. In this study, 100 µM calycosin for 48h showed protective effect against PQ-induced neurodegeneration, as revealed by better locomotor performance and increased fly survival, by modulating oxidative stress signaling and neuronal cell death, improving mitochondrial functions, and restoring autophagy [209].…”

Section: Isoflavones In Alzheimer's (Ad) and Parkinson's Diseases (Pd)mentioning

confidence: 99%

Flavonoids bridging the gut and the brain: Intestinal metabolic fate, and direct or indirect effects of natural supporters against neuroinflammation and neurodegeneration

Magni

Riboldi

Petroni

et al. 2022

Biochemical Pharmacology

View full text Add to dashboard Cite

Antioxidant activity of calycosin against α-synuclein amyloid fibrils-induced oxidative stress in neural-like cells as a model of preventive care studies in Parkinson's disease

Cited by 24 publications

References 33 publications

Neuroprotective Effects of Bifidobacterium breve CCFM1067 in MPTP-Induced Mouse Models of Parkinson’s Disease

Neuroprotective Effects of Bifidobacterium breve CCFM1067 in MPTP-Induced Mouse Models of Parkinson’s Disease

Parkinson's Disease: Current Status, Diagnosis, and Treatment Using Nanomedicines

Flavonoids bridging the gut and the brain: Intestinal metabolic fate, and direct or indirect effects of natural supporters against neuroinflammation and neurodegeneration

Contact Info

Product

Resources

About